NOTE: CERTAIN PORTIONS OF THE EXHIBITS TO THIS LETTER AGREEMENT, WHICH ARE IDENTIFIED BY THE SYMBOL “[* *]”, HAVE BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST.Letter Agreement • August 12th, 2003 • Pozen Inc /Nc • Pharmaceutical preparations
We refer to that certain Product Development and Commercialization Agreement, dated as of the date hereof (the “Agreement”), by and between POZEN INC., a Delaware corporation (“POZEN”), and Glaxo Group Ltd., a corporation organized under the laws of England, doing business as GlaxoSmithKline (“GSK”). Capitalized terms used but not otherwise defined herein will have the meanings assigned to such terms in the Agreement. In connection with the execution and delivery of the Agreement and the consideration set forth therein, POZEN and GSK hereby enter into this Letter Agreement and agree as follows:
POZEN INC. / NYCOMED DANMARK APS LICENSE AGREEMENTLicense Agreement • August 12th, 2003 • Pozen Inc /Nc • Pharmaceutical preparations • North Carolina
THIS LICENSE AGREEMENT (the “Agreement”) is made and entered into as of June 30, 2003 (the “Effective Date”), by and between POZEN INC., a Delaware corporation (“POZEN”), with a business address of 1414 Raleigh Road, Suite 400, Chapel Hill, NC 27517, and NYCOMED DANMARK APS, a Danish corporation (“Licensee” or “Nycomed”), located at Langebjerg 1, DK-4000 Roskilde, Denmark. POZEN and Licensee are referred to in this Agreement individually as a “Party” and collectively as “Parties.”
PRODUCT DEVELOPMENT AND COMMERCIALIZATION AGREEMENTCommercialization Agreement • August 12th, 2003 • Pozen Inc /Nc • Pharmaceutical preparations • North Carolina
THIS PRODUCT DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (the “Agreement”) is executed as of June 11, 2003 (“Execution Date”) by and between POZEN INC., a Delaware corporation (“POZEN”), and Glaxo Group Ltd., a corporation organized under the laws of England, doing business as GlaxoSmithKline (“GSK”). POZEN and GSK are sometimes referred to herein each individually as a “Party” and collectively as the “Parties.”
